Biorecognition of HPMA copolymer-lectin conjugates as an indicator of differentiation of cell-surface glycoproteins in development, maturation, and diseases of human and rodent gastrointestinal tissues

Citation
S. Wroblewski et al., Biorecognition of HPMA copolymer-lectin conjugates as an indicator of differentiation of cell-surface glycoproteins in development, maturation, and diseases of human and rodent gastrointestinal tissues, J BIOMED MR, 51(3), 2000, pp. 329-342
Citations number
48
Categorie Soggetti
Multidisciplinary
Journal title
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH
ISSN journal
00219304 → ACNP
Volume
51
Issue
3
Year of publication
2000
Pages
329 - 342
Database
ISI
SICI code
0021-9304(20000905)51:3<329:BOHCCA>2.0.ZU;2-Q
Abstract
Lectins are proteins that bind glycoproteins; binding patterns are altered with changes in glycoprotein expression accompanying maturation or disease. Binding of two lectins, wheat germ agglutinin (WGA) and peanut agglutinin (PNA), in human and rodent colon were previously examined. Normal tissue sh owed intense WGA binding; PNA binding was minimal. Diseased tissues showed increased PNA binding. We hypothesized that N-(2-hydroxypropyl)methacrylami de (HPMA) copolymer-lectin-drug conjugates could deliver therapeutic agents to diseased tissues by targeting colonic glycoproteins. We examined biorec ognition of free and HPMA copolymer-conjugated WGA and PNA and anti-Thomsen -Friedenreich (TF) antigen antibody binding in normal neonatal, adult, and diseased rodent tissues, human specimens of inflammation, and Barrett's eso phagus. Neonatal WGA binding was comparable to the adult, with additional l uminal columnar cell binding. PNA binding was more prevalent; luminal colum nar cell binding existed during the first 2.5 weeks of Life. WGA binding wa s strong in both normal and diseased adult tissues; a slight decrease was n oted in disease. PNA binding was minimal in normal tissues; increases were seen in disease. Anti-TF antigen antibody studies showed that PNA did not b ind to the antigen. The results suggest that HPMA copolymer-lectin-drug con jugates may provide site-specific treatment of conditions such as colitis a nd Barrett's esophagus. (C) 2000 John Wiley & Sons, Inc.